Risk Communication panel inception
FDA will convene the first meeting of its new Risk Communication Advisory Committee Feb. 28 to discuss the agency's risk communication programs and regulatory responsibilities. The committee is charged with advising FDA on methods to effectively communicate the risks associated with all products, including those that emerge after a product is on the market. On Feb. 29, the panel will advise FDA on best risk-communication practices for the agency's proposed template for press releases announcing product recalls. The advisory panel was established in response to a recommendation by the Institute of Medicine as part of its evaluation of the U.S. drug safety system (1"The Pink Sheet" Nov. 12, 2007, p. 8)...
You may also be interested in...
Facing soaring legal costs stemming from its failed merger with Fresenius Kabi and burdened by substantial debt, Akorn elected to put itself up for sale earlier this year in order to help repay lenders. But the company has now defaulted on an agreement with its creditors after no bidder stepped up to the plate.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.